Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women’s Health
VIVJOA provided nearly 2 years of sustained efficacy against RVVC in a long-term extension of Phase 3 studies Mycovia Pharmaceuticals, Inc. (“Mycovia”) has announced the publication of long-term efficacy results from an extension study of the VIOLET Phase 3 clinical program which evaluated VIVJOA (oteseconazole) capsules in women with RVVC in the Journal of Women's […]